Amalgamated Financial’s Seres Therapeutics MCRB Stock Holding History

Amalgamated Financial’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$81K	Buy	+567	New	+$87.2K	﹤0.01%	2233

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Amalgamated Financial's MCRB Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Seres Therapeutics (MCRB) in Q1 2022: 567 shares worth $81K. The stake represents ﹤0.01% of the portfolio and ranks #2233 among its holdings.

131 funds tracked by Wall St. Rank hold MCRB as of Q1 2022.

Amalgamated Financial held 567 shares of Seres Therapeutics worth $81K as of Q1 2022.
Seres Therapeutics was a new Amalgamated Financial position in Q1 2022.
Seres Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2233 holding.
131 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.